echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Clin Cancer Res: A new CIP2A mutant (NOCIVA) that can predict TKI resistance in myeloid leukemia

    Clin Cancer Res: A new CIP2A mutant (NOCIVA) that can predict TKI resistance in myeloid leukemia

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    PP2A cancer suppressor factor (CIP2A) is an oncoprotein that inhibits the tumor suppressor gene PP2A-B56a.


    Recently, Eleonora et al.


    CIP2A mutants were identified by 3'and 5'rapid amplification of cancer cell cDNA ends.


    NOCIVA mutant

    NOCIVA mutant

    The NOCIVA mutant contains exons 1-13 and fused 349 nucleotides from intron 13.


    The NOCIVA mutant contains exons 1-13 and fused 349 nucleotides from intron 13.


    NOCIVA is enriched in the nucleus

    NOCIVA is enriched in the nucleus

    NOCIVA retains the ability to bind to B56a, but CIP2A is mainly a cytoplasmic protein, and NOCIVA is transferred to the nucleus.


    Samples from AML and CML patients overexpress NOCIVA but not CIP2A mRNA, which indicates that alternative splicing from CIP2A to NOCIVA is common in myeloid malignancies.


    The correlation between the expression level of NOCIVA/CIP2A and the prognostic survival rate of patients

    The correlation between the expression level of NOCIVA/CIP2A and the prognostic survival rate of patients

    In AML, high NOCIVA/CIP2A mRNA expression rate is a sign of low overall survival rate.


    In AML, high NOCIVA/CIP2A mRNA expression rate is a sign of low overall survival rate.


    Eleonora et al.


    Original source:

    Makela Eleonora, Pavic Karolina, Varila Taru M et al.


    aacrjournals.
    org/content/early/2021/03/04/1078-0432.
    CCR-20-3679" target="_blank" rel="noopener">Discovery of a Novel CIP2A Variant (NOCIVA ) with clinical relevance in predicting TKI resistance in myeloid leukemias in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.